SciSparc Highlights Recruitment Of First Patient For Its Phase 2a Trial In Alzheimer’s Disease
SciSparc Ltd. (NASDAQ:SPRC) (the "Company"), a clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that The Israeli